Authors
Latest:
Orchestrating ComplianceProduct managers would be less disrupted if compliance activities at pharma companies were more anticipatory than reactionary.
Latest:
Shire to Relocate More Than 500 Jobs to Lexington, MAShire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, PA, site and establish Lexington, MA, as the company’s US operational headquarters.
Latest:
Combating CounterfeitsAfter last year's anthrax scare, people desperately began stockpiling Cipro (ciprofloxacin) and other products to prepare for bioterrorism attacks. Not wanting to bother with a visit to their doctor and not willing to pay the product's high retail price of several dollars a pill, they began ordering Cipro-or what they believed to be Cipro-online, from dozens of websites offering it at discounted rates. The problem is, there is no guarantee they were getting the real thing.
Latest:
Get a Grip on the Supply ChainThe Sarbanes-Oxley Act-or SOX, as it is dubbed (not always so affectionately)-requires companies to provide greater control and quality assurance across a vast spectrum of business processes. In practice, SOX plays out differently industry by industry and even company by company. But for pharma, one of the most pressing consequences is the need to improve the accuracy of revenue recognition.
Latest:
Marketing to Professionals: Everyone's a ComedianHave the confidence to step outside the norm. A targeted, humorous campaign will attract attention more quickly.
Latest:
Sales SlipOne fortunate consequence of a slower job market is that tenure levels are increasing: 80 percent of sales managers now have at least two years experience under their belt.
Latest:
The Ins and Outs of EAPsFor a patient who is running out of hope, waiting for a drug to be approved can be interminable. Even on the fast track, a review can take six months or longer. Some patients with life-threatening diseases cannot afford to wait. In response, many countries have developed expanded access programs (EAPs) that give patients with no other viable alternative access to medically important drugs before they are commercialized.
Latest:
Sales Management: Cleaning HouseWith fewer feet on the street because of downsizing at many drug firms, sales reps and managers need to work smarter-and that means working with information that's both accurate and up to date
Latest:
The List: 2011It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!
Latest:
Making the SwitchDr. Doug Bierer felt like he was in a courtroom, waiting for the jury to render its verdict. It was June 2002, and executives from Procter & Gamble and its partner AstraZeneca had just finished presenting their bid to FDA's Non-Prescription Drugs Advisory Committee (NDAC) to market the popular heartburn medication, Prilosec (omeprazole), as an over-the-counter (OTC) drug.
Latest:
Marketing to Professionals: The Advertorial EffectAdvertorials were shown to be more effective than branded ads in terms of generating interest, providing valuable info, and provoking follow-up discussions
Latest:
How to Keep Out of Regulatory QuicksandOIG now requires corporate marketing departments and field sales reps to not only document how they promote products, but to also-for the first time-demonstrate the "intent" of marketing activities.
Latest:
Generics Battle Heats UpThe competition for generics' 180-day marketing exclusivity is fierce, and Dr. Reddy's Laboratories filed the first court case calling into question FDA's methods for determining exclusivity on a patent-by-patent basis.
Latest:
When Accessing Healthcare Value is in the Eye of the BeholderAs patients pay more healthcare expenses directly from their own pockets, the industry must look at patients' ability to pay alongside willingness to pay to understand the various factors of patient decisions to accept or decline treatment.
Latest:
Protecting IP Throughout the Product LifecycleNow that patents on several blockbuster drugs have expired, the industry-feeling the pinch-has focused its attention on intellectual property. Because every additional month of market exclusivity can mean an extra $50 million or more in revenue, pharma companies have gone to great lengths to block the entry of generic competition.
Latest:
Digital Alternatives Define New Sales ForceTeams must adapt techniques to embrace new technologies in order to remain successful
Latest:
India: An Emerging Knowledge Superpower"India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub." For Dilip Shah, General Secretary of the Indian Pharmaceutical Alliance (IPA), India is currently on its way to undertake one of the greatest transformations ever experienced within the pharmaceutical industry, although the excitement has been over 30 years in the making.
Latest:
Drug Promotion to Docs on the DefensiveCanberra, Australia-The Australian Pharmaceutical Manufacturers' Association has denounced calls from the country's media and some of its doctors to drastically curtail drug promotion. APMA chief executive Alan Evans says any such move would severely affect the healthcare of millions of people in Australia and could even result in premature death.
Latest:
Can Med Tech Follow Pharma's Lead in Patient Advocacy?The drive towards greater patient centricity in the med tech industry has been reinforced by new EMA legislation. Can med tech follow pharma's example in engaging with patient advocates?
Latest:
How Pharma’s Checks and Balances Can Help Fight Its Public PerceptionWhat can we do to prevent such blatant black eyes to the industry so many of us love?
Latest:
Legal: Foreign PolicyCompliance requires overcoming cultural barriers. To start with, in some countries the taboo against bribery is not as strong as it is here.
Latest:
Doctor's OrdersDr. Michael Kessler and Mark Vitello of MD Mindset have the cure for the common sales pitch? Look at the transaction from the customer's perspective
Latest:
Finding the Translators: Helping Connect the Science to the PatientThe need for analytics translators is not limited to data science. The adoption of all scientific or technical advances, including those in the healthcare industry, needs effective translators. So what does this mean for pharma marketing?
